Amphastar To Get $60M In Settlement With Rivals

Law360 (June 19, 2019, 3:48 PM EDT) -- Amphastar Pharmaceuticals Inc. announced Wednesday it will receive nearly $60 million from two rival drug companies as part of a settlement to resolve an antitrust and patent suit.

Sandoz and Momenta Pharmaceuticals will pay $59.9 million to Amphastar as part of a deal to end antitrust and patent litigation over the blood-thinner enoxaparin, the generic version of Sanofi-Aventis’ Lovenox, Amphastar said Wednesday. (Getty)

According to the terms of the settlement, Sandoz Inc. and Momenta Pharmaceuticals Inc. will pay $59.9 million to Amphastar by July 2, and a pending antitrust suit and a patent verdict will be nixed.

A brief U.S. Securities...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS